MA38493B1 - Composés tricycliques utilisés en tant qu'inhibiteurs de l'immunosuppression dont la médiation est assurée par la métabolisation du tryptophane - Google Patents
Composés tricycliques utilisés en tant qu'inhibiteurs de l'immunosuppression dont la médiation est assurée par la métabolisation du tryptophaneInfo
- Publication number
- MA38493B1 MA38493B1 MA38493A MA38493A MA38493B1 MA 38493 B1 MA38493 B1 MA 38493B1 MA 38493 A MA38493 A MA 38493A MA 38493 A MA38493 A MA 38493A MA 38493 B1 MA38493 B1 MA 38493B1
- Authority
- MA
- Morocco
- Prior art keywords
- tryptophan
- treat
- immunosuppression
- inhibitors
- metabolism
- Prior art date
Links
- 206010062016 Immunosuppression Diseases 0.000 title abstract 4
- 230000001506 immunosuppresive effect Effects 0.000 title abstract 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 title abstract 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 230000004060 metabolic process Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 abstract 1
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 abstract 1
- 238000011394 anticancer treatment Methods 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 abstract 1
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne des inhibiteurs d'ido et de tdo et des compositions pharmaceutiques les comprenant, qui peuvent être utilisés pour moduler une activité de l'indoleamine 2,3-dioxygénase et de la tryptophane 2,3 dioxygénase ; traiter l'immunosuppression ; traiter des états pathologiques qui sont améliorés par inhibition de la dégradation du tryptophane ; augmenter l'efficacité d'un traitement anticancéreux qui consiste à administrer un agent anticancéreux ; traiter l'immunosuppression spécifique d'une tumeur associée à un cancer ; et traiter l'immunosuppression associée à une maladie infectieuse.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361784089P | 2013-03-14 | 2013-03-14 | |
PCT/US2014/022680 WO2014159248A1 (fr) | 2013-03-14 | 2014-03-10 | Composés tricycliques utilisés en tant qu'inhibiteurs de l'immunosuppression dont la médiation est assurée par la métabolisation du tryptophane |
Publications (2)
Publication Number | Publication Date |
---|---|
MA38493A1 MA38493A1 (fr) | 2017-02-28 |
MA38493B1 true MA38493B1 (fr) | 2017-10-31 |
Family
ID=50686105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38493A MA38493B1 (fr) | 2013-03-14 | 2014-03-10 | Composés tricycliques utilisés en tant qu'inhibiteurs de l'immunosuppression dont la médiation est assurée par la métabolisation du tryptophane |
Country Status (22)
Country | Link |
---|---|
US (2) | US9617272B2 (fr) |
EP (2) | EP2976332B1 (fr) |
JP (2) | JP6093903B2 (fr) |
KR (1) | KR20150126623A (fr) |
CN (1) | CN105189466A (fr) |
AU (2) | AU2014241079C1 (fr) |
BR (1) | BR112015022588A2 (fr) |
CA (1) | CA2902174A1 (fr) |
CL (2) | CL2015002649A1 (fr) |
CR (1) | CR20150485A (fr) |
HK (1) | HK1213259A1 (fr) |
IL (1) | IL241027A0 (fr) |
MA (1) | MA38493B1 (fr) |
MX (1) | MX361375B (fr) |
PE (1) | PE20151593A1 (fr) |
PH (1) | PH12015501866A1 (fr) |
RU (1) | RU2667509C2 (fr) |
SA (1) | SA515361127B1 (fr) |
SG (2) | SG10201707545XA (fr) |
UA (1) | UA118103C2 (fr) |
WO (1) | WO2014159248A1 (fr) |
ZA (1) | ZA201607948B (fr) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO2694640T3 (fr) | 2011-04-15 | 2018-03-17 | ||
TWI644671B (zh) | 2013-03-14 | 2018-12-21 | 比利時商健生藥品公司 | P2x7調節劑 |
US10053463B2 (en) | 2013-03-14 | 2018-08-21 | Janssen Pharmaceutica Nv | Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators |
US9096596B2 (en) | 2013-03-14 | 2015-08-04 | Janssen Pharmaceutica Nv | P2X7 modulators |
ES2845473T3 (es) | 2013-03-14 | 2021-07-26 | Boehringer Ingelheim Int | (Bencil-ciano-metil)-amidas sustituidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico inhibidores de la catepsina- C |
JO3509B1 (ar) | 2013-03-14 | 2020-07-05 | Janssen Pharmaceutica Nv | معدلات p2x7 |
CN103570727B (zh) | 2013-11-12 | 2015-08-19 | 复旦大学 | 一种n-苄基色胺酮衍生物及其制备方法和应用 |
CA2956465A1 (fr) | 2014-09-05 | 2016-03-10 | Merck Patent Gmbh | Composes diaza- et triaza- tricycliques a cyclohexyl-ethyle substitue comme antagonistes de l'indoleamine 2,3-dioxygenase (ido) pour le traitement du cancer |
EP3191492B1 (fr) | 2014-09-12 | 2019-01-09 | Janssen Pharmaceutica NV | Modulateurs de p2x7 |
DK3191487T3 (da) | 2014-09-12 | 2019-10-28 | Boehringer Ingelheim Int | Spirocykliske cathepsin-c-inhibitorer |
GB201417369D0 (en) * | 2014-10-01 | 2014-11-12 | Redx Pharma Ltd | Compounds |
US20160145344A1 (en) * | 2014-10-20 | 2016-05-26 | University Of Southern California | Murine and human innate lymphoid cells and lung inflammation |
CA2965741C (fr) * | 2014-11-03 | 2022-05-17 | Iomet Pharma Ltd | Compose pharmaceutique |
WO2016100851A1 (fr) | 2014-12-18 | 2016-06-23 | Lankenau Institute For Medical Research | Procédés et compositions pour le traitement de la rétinopathie et d'autres maladies oculaires |
CN105884828A (zh) * | 2015-02-16 | 2016-08-24 | 上海迪诺医药科技有限公司 | 多环化合物、其药物组合物及应用 |
JP6806342B2 (ja) * | 2015-04-10 | 2021-01-06 | ベイジーン リミテッド | インドールアミンとしての新規5又は8−置換イミダゾ[1,5−a]ピリジン類、及び/又はトリプトファン2,3−ジオキシゲナーゼ |
JP2018511647A (ja) | 2015-04-12 | 2018-04-26 | ハンジョウ イノゲート ファーマ カンパニー リミテッドHangzhou Innogate Pharma Co.,Ltd. | Ido阻害剤とtdo阻害剤としての複素環化合物 |
US9951065B2 (en) * | 2015-05-15 | 2018-04-24 | Gilead Sciences, Inc. | Benzimidazole and imadazopyridine carboximidamide compounds |
GB2548542A (en) * | 2015-06-16 | 2017-09-27 | Redx Pharma Plc | Compounds |
CN105037371A (zh) * | 2015-06-30 | 2015-11-11 | 西华大学 | 一种氘代的吲哚胺-2,3-双加氧酶抑制剂 |
CN107847486A (zh) | 2015-07-24 | 2018-03-27 | 新联基因公司 | 1‑甲基‑d‑色氨酸的盐和前药 |
US10800780B2 (en) | 2015-12-24 | 2020-10-13 | Genentech, Inc. | TDO2 Inhibitors |
CN107056785B (zh) * | 2016-01-02 | 2021-06-22 | 杭州英创医药科技有限公司 | 作为ido和tdo抑制剂的杂环化合物 |
EP3400226A1 (fr) | 2016-02-02 | 2018-11-14 | Emcure Pharmaceuticals Limited | Dérivés de pyrroloimidazole ou analogues de ceux-ci utiles, entre autres, dans le traitement du cancer |
WO2017140274A1 (fr) * | 2016-02-19 | 2017-08-24 | 正大天晴药业集团股份有限公司 | Composé tricyclique servant d'immunomodulateur |
TW201736373A (zh) * | 2016-02-19 | 2017-10-16 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | 作為免疫調節劑的三並環化合物 |
WO2017149469A1 (fr) | 2016-03-03 | 2017-09-08 | Emcure Pharmaceuticals Limited | Composés hétérocycliques utiles en tant que modulateurs de l'ido et/ou de la tdo |
KR102456521B1 (ko) * | 2016-04-29 | 2022-10-20 | 아이오메트 파마 엘티디 | 인돌아민 2,3-디옥시게나제 및/또는 트립토판-2,3-디옥시게나제의 억제제로서의 신규 치환된 이미다조피리딘 화합물 |
WO2017198159A1 (fr) * | 2016-05-16 | 2017-11-23 | 鲁南制药集团股份有限公司 | Dérivé d'imidazole contenant un cycle de liaison |
CN107383012B (zh) * | 2016-05-16 | 2021-09-28 | 鲁南制药集团股份有限公司 | 含二环的咪唑醇衍生物 |
CN107663159A (zh) * | 2016-07-29 | 2018-02-06 | 上海迪诺医药科技有限公司 | 多环化合物、其药物组合物及应用 |
JP7358236B2 (ja) | 2016-09-19 | 2023-10-10 | ユニヴァーシティ オブ サウス フロリダ | 腫瘍溶解性ウイルスを腫瘍に標的化する方法 |
TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ido及tdo調節之化合物及方法以及其適應症 |
CN109952300B (zh) | 2016-09-24 | 2022-01-18 | 百济神州有限公司 | 5或8-取代的咪唑并[1,5-a]吡啶 |
EP3525803B1 (fr) | 2016-10-13 | 2022-12-07 | Juno Therapeutics, Inc. | Méthodes et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane |
WO2018072742A1 (fr) * | 2016-10-21 | 2018-04-26 | 江苏恒瑞医药股份有限公司 | Forme cristalline de base libre de dérivé d'imidazo-isoindole et son procédé de préparation |
EP3560928B1 (fr) * | 2016-12-20 | 2021-10-20 | Shenzhen Chipscreen Biosciences Co., Ltd. | Composé imidazole fusionné ayant une activité inhibitrice de l'indoléamine 2,3-dioxygénase |
NZ754364A (en) | 2016-12-22 | 2023-04-28 | Calithera Biosciences Inc | Compositions and methods for inhibiting arginase activity |
JP2020506895A (ja) | 2017-01-17 | 2020-03-05 | ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | インドールアミン2,3−ジオキシゲナーゼおよび/またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物 |
EP3645537A1 (fr) | 2017-06-28 | 2020-05-06 | Genentech, Inc. | Inhibiteurs de tdo2 et ido1 |
US11603373B2 (en) | 2017-06-28 | 2023-03-14 | Genentech, Inc. | TDO2 and IDO1 inhibitors |
CN109384791B (zh) * | 2017-08-09 | 2020-09-11 | 江苏恒瑞医药股份有限公司 | 一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法 |
EP3682900A4 (fr) * | 2017-09-15 | 2021-06-16 | Taiho Pharmaceutical Co., Ltd. | Agent prophylactique et/ou thérapeutique pour des maladies impliquant l'expression de l'ido |
JP7306634B2 (ja) * | 2017-10-19 | 2023-07-11 | 一般社団法人ファルマバレープロジェクト支援機構 | Ido/tdo阻害剤 |
US11472788B2 (en) | 2017-11-25 | 2022-10-18 | Beigene, Ltd. | Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases |
CA3084829A1 (fr) | 2018-01-05 | 2019-07-11 | Dicerna Pharmaceuticals, Inc. | Diminution de l'expression de la beta-catenine et de ido pour potentialiser une immunotherapie |
JP2021518367A (ja) | 2018-03-20 | 2021-08-02 | プレキシコン インコーポレーテッドPlexxikon Inc. | Idoおよびtdo調節のための化合物および方法、ならびにそれらのための兆候 |
EP3823604A4 (fr) | 2018-07-17 | 2022-03-16 | Board of Regents, The University of Texas System | Composés utiles en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase et/ou de la tryptophane dioxygénase |
WO2020065613A1 (fr) | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Modulateurs de la monoacylglycérol lipase |
MX2021003661A (es) | 2018-09-28 | 2021-08-19 | Janssen Pharmaceutica Nv | Moduladores de la monoacilglicerol lipasa. |
US11839663B2 (en) | 2019-09-30 | 2023-12-12 | Janssen Pharmaceutica Nv | Radiolabelled MGL pet ligands |
WO2021191359A1 (fr) | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Modulateurs de la monoacylglycérol lipase |
US11839659B2 (en) | 2020-07-02 | 2023-12-12 | Northwestern University | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein |
EP4052705A1 (fr) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions pour le traitement des maladies ou des pathologies associées à l'ebv |
BR112023017582A2 (pt) | 2021-03-05 | 2023-12-05 | Univ Basel | Composições para o tratamento de doenças ou condições associadas ao ebv |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH516573A (de) * | 1967-08-15 | 1971-12-15 | Sandoz Ag | Verfahren zur Herstellung von 5-Hydroxy-5-phenyl-2,3-dihydro-5H-imidazo(2,1-a)isoindolen |
US5807892A (en) | 1994-09-30 | 1998-09-15 | Alcon Laboratories, Inc. | Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension |
WO1999029852A1 (fr) | 1997-12-05 | 1999-06-17 | Medical College Of Georgia Research Institute, Inc. | Transporteur de tryptophane d'affinite elevee |
EP1501918A4 (fr) | 2002-04-12 | 2006-03-29 | Med College Georgia Res Inst | Populations de cellules presentatrices de l'antigene et leur utilisation comme reactifs pour renforcer ou diminuer la tolerance immunitaire |
JP2006502097A (ja) | 2002-05-15 | 2006-01-19 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Pdgf受容体阻害剤としてのn−置換三環状3−アミノピラゾール |
JP2006521377A (ja) | 2003-03-27 | 2006-09-21 | ランケナー インスティテュート フォー メディカル リサーチ | 新型ido阻害剤とその使用方法 |
DE102007020493A1 (de) | 2007-04-30 | 2008-11-06 | Grünenthal GmbH | Substituierte Amid-Derivate |
JP5583592B2 (ja) | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | Ido阻害剤 |
EP2291187B1 (fr) * | 2008-04-24 | 2018-08-15 | Newlink Genetics Corporation | Inhibiteurs des ido |
EP2365748A4 (fr) * | 2008-11-13 | 2012-05-02 | Merck Sharp & Dohme | Antagonistes imidazoisoindoles des récepteurs du neuropeptide s |
WO2011056652A1 (fr) * | 2009-10-28 | 2011-05-12 | Newlink Genetics | Dérivés imidazole comme inhibiteurs de l'ido |
JP2012037986A (ja) | 2010-08-04 | 2012-02-23 | Canon Inc | 画像形成装置及びその制御方法と画像形成システム |
NO2694640T3 (fr) * | 2011-04-15 | 2018-03-17 |
-
2014
- 2014-03-10 US US14/774,450 patent/US9617272B2/en not_active Expired - Fee Related
- 2014-03-10 PE PE2015001907A patent/PE20151593A1/es not_active Application Discontinuation
- 2014-03-10 CN CN201480015368.3A patent/CN105189466A/zh active Pending
- 2014-03-10 JP JP2016501035A patent/JP6093903B2/ja not_active Expired - Fee Related
- 2014-03-10 AU AU2014241079A patent/AU2014241079C1/en not_active Ceased
- 2014-03-10 EP EP14722814.2A patent/EP2976332B1/fr not_active Not-in-force
- 2014-03-10 MA MA38493A patent/MA38493B1/fr unknown
- 2014-03-10 SG SG10201707545XA patent/SG10201707545XA/en unknown
- 2014-03-10 SG SG11201507255QA patent/SG11201507255QA/en unknown
- 2014-03-10 EP EP18152869.6A patent/EP3366678A1/fr not_active Withdrawn
- 2014-03-10 WO PCT/US2014/022680 patent/WO2014159248A1/fr active Application Filing
- 2014-03-10 MX MX2015011385A patent/MX361375B/es active IP Right Grant
- 2014-03-10 RU RU2015143990A patent/RU2667509C2/ru not_active IP Right Cessation
- 2014-03-10 BR BR112015022588A patent/BR112015022588A2/pt not_active Application Discontinuation
- 2014-03-10 CA CA2902174A patent/CA2902174A1/fr not_active Abandoned
- 2014-03-10 KR KR1020157025259A patent/KR20150126623A/ko not_active Application Discontinuation
- 2014-10-03 UA UAA201510014A patent/UA118103C2/uk unknown
-
2015
- 2015-08-25 PH PH12015501866A patent/PH12015501866A1/en unknown
- 2015-09-01 IL IL241027A patent/IL241027A0/en unknown
- 2015-09-11 CL CL2015002649A patent/CL2015002649A1/es unknown
- 2015-09-14 SA SA515361127A patent/SA515361127B1/ar unknown
- 2015-09-14 CR CR20150485A patent/CR20150485A/es unknown
-
2016
- 2016-02-04 HK HK16101323.8A patent/HK1213259A1/zh not_active IP Right Cessation
- 2016-08-01 CL CL2016001940A patent/CL2016001940A1/es unknown
- 2016-11-14 JP JP2016221202A patent/JP6352368B2/ja not_active Expired - Fee Related
- 2016-11-17 ZA ZA2016/07948A patent/ZA201607948B/en unknown
-
2017
- 2017-02-16 US US15/434,414 patent/US9981973B2/en not_active Expired - Fee Related
- 2017-03-13 AU AU2017201693A patent/AU2017201693A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38493B1 (fr) | Composés tricycliques utilisés en tant qu'inhibiteurs de l'immunosuppression dont la médiation est assurée par la métabolisation du tryptophane | |
MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
EA202090871A1 (ru) | Ингибирование убиквитин-специфической пептидазы 30 | |
EA201691079A1 (ru) | Комбинированная терапия для лечения онкологического заболевания | |
EA201890009A1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
EA201790674A1 (ru) | Индуцирующий цитотоксичность терапевтический агент | |
EA201891248A1 (ru) | Пролекарства jak-ингибирующего соединения для лечения воспалительного заболевания желудочно-кишечного тракта | |
CY1117440T1 (el) | Συτηκτα παραγωγα ιμιδαζολης ως αναστολεις toy ido | |
JOP20160092B1 (ar) | علاج البيتا ثلاسيميا باستخدام مصطبة لجائنية | |
MA38483A1 (fr) | Inhibiteurs de l'ido | |
EA201790992A1 (ru) | Иммунорегуляторные агенты | |
MA38986B1 (fr) | Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate | |
MA40768B1 (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
AR101177A1 (es) | Inhibidores de la syk | |
EA201990240A1 (ru) | Новые трициклические соединения в качестве противораковых средств | |
CU20150163A7 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
MX346147B (es) | Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico. | |
MA40875B1 (fr) | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux | |
EA201892834A1 (ru) | Комбинированная химиотерапия | |
EA201691570A1 (ru) | Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента | |
EA202091020A1 (ru) | Замещенные имидазопиридинамиды и их применение | |
EA202192905A1 (ru) | Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли | |
EA201990567A1 (ru) | Комбинированная терапия с ингибиторами глутаминазы | |
MA48728B1 (fr) | Niraparib, acétate d'abiratérone et prednisone pour le traitement du cancer de la prostate | |
CY1126079T1 (el) | Σκευασματα καψουλας |